Search Medical Condition
Please enter condition
Please choose location from dropdown

Saint Denis Cedex 01, France Clinical Trials

A listing of Saint Denis Cedex 01, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (1703) clinical trials

Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen

The study objective is to determine in a high bleeding risk patient population undergoing PCI under standardized treatment (within current guidelines and instructions for use and including the bioresorbable polymer coated Ultimaster sirolimus-eluting stent), whether abbreviated DAPT is non-inferior to prolonged DAPT regimen in terms of NACE within 12 months, ...

Phase N/A

0.0 miles

Learn More »

A Study of Melflufen-dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide

This is a randomized, controlled, open-label, Phase 3 multicenter study which will enroll patients with RRMM following 2-4 lines of prior therapy and who are refractory to lenalidomide in the last line of therapy as demonstrated by disease progression on or within 60 days of completion of the last dose ...

Phase

0.0 miles

Learn More »

Micra Transcatheter Pacing System Post-Approval Registry

The Micra Registry is a global, prospective, observational, multi-site registry. Patients enrolled in the Micra Registry will be prospectively followed for a minimum of 9 years post-implant or until registry closure, patient death, patient exit from the registry (i.e., withdrawal of consent), or unless patient is participating in an acute ...

Phase N/A

0.0 miles

Learn More »

Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML

ARM A: DECITABINE (DAC) Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Treatment will be delayed at the discretion of the investigator (up to D56) for febrile neutropenia ( 38.5C; absolute neutrophil count [ANC], < 1,000/L), clinical and/or microbiologic infection with grade ...

Phase

0.0 miles

Learn More »

A clinical trial to evaluate treatments for patients with Atrial Fibrillation, Thrombosis

Atrial fibrillation is the most frequent heart rhythm disorder. Its symptomatic forms, resistant to drug therapy, require invasive management (catheter ablation), which exposes to potentially serious complications including thromboembolic complications. Despite anticoagulant treatment, intra-atrial thrombus, which is a contraindication to catheter ablation, is detected in nearly 2 % of cases. ...

Phase N/A

0.0 miles

Learn More »

Prognostic Assessment of Diastolic and Systolic Left Ventricular Function in Septic Shock

Consecutive patients diagnosed with septic shock will be followed daily using echocardiography from Day1 (first echocardiography performed within 12h after the diagnosis of septic shock) to Day3, after vasopressor discontinuation (Day end), and on Day28 or at hospital discharge (if occurs before Day28). Echocardiographic data will be anonymized and stored ...

Phase N/A

0.0 miles

Learn More »

Extra Hospital Delivery Outside Medical Presence.

This study aims to evaluate a standardized procedure of medical regulation based on a validated predictive score of eminent delivery (SPIA) in comparison with usual inhomogeneous practices. It will therefore focus on the issues of medical regulation at SAMU - Center 15. The goal of the regulator is to provide ...

Phase N/A

0.0 miles

Learn More »

Comparison of 3 Diagnostic Strategies of PE: Planar V/Q Scan CTPA and V/Q SPECT.

Pulmonary embolism (PE) remains a diagnostic challenge. False negative testing exposes patient to the risk of potentially fatal recurrence. False positive testing exposes patients to potentially fatal unduly side effects of anticoagulants. Current diagnostic strategies rely on the sequential use of pretest clinical probability, Ddimer test, and chest imaging. Two ...

Phase N/A

0.0 miles

Learn More »

Denosumab and Nivolumab Combination as 2d-line Therapy in Stage IV NSC Lung Cancer With Bone Metastases (DENIVOS)

Bone metastases are common in Non-Small Cell Lung Cancer (NSCLC), affecting 30-65% of the patients, depending on the series. They most often occur during disease progression (59.7% in the French Lung Cancer Group trial). The frequency of skeletal-related events (SREs) (pathological fractures, medullary compression, analgesic radiotherapy, preventive and/or analgesic surgery ...

Phase

0.0 miles

Learn More »